Market Overview

UPDATE: Barclays Begins Coverage on Cerner and Advisory Board

Related CERN
Benzinga's Top Initiations
Benzinga's Top Downgrades
Related ABCO
20 Biggest Mid-Day Gainers For Thursday
Credit Suisse All Aboard The Advisory Board

Barclays Wednesday reports includes a note from analyst Eric Percher for coverage initiation on Cerner (NASDAQ: CERN) and The Advisory Board Company (NASDAQ: ABCO) with an Overweight rating for each company. Price target of $79.

Percher notes, "Given our findings that the transition to value-based reimbursement and implementation of population health tools on a large scale will be at least a five- to seven-year journey, we favor companies that either provide services which will enable the journey itself or have demonstrated opportunities to drive growth outside of population health offerings. We believe no company is better positioned to advise hospital leadership than Advisory Board and Cerner's diversified growth strategy should drive double-digit growth even absent meaningful population health contributions."

ABCO closed Tuesday at $66.79 and opened Wednesday morning at $67. CERN closed previous session at $61.86 and opened at $61.94.

Latest Ratings for CERN

Oct 2016UBSInitiates Coverage onNeutral
Sep 2016Bank of AmericaInitiates Coverage onBuy
Sep 2016Cowen & Co.DowngradesOutperformMarket Perform

View More Analyst Ratings for CERN
View the Latest Analyst Ratings

Posted-In: BarclaysPrice Target Initiation Analyst Ratings


Related Articles (ABCO + CERN)

View Comments and Join the Discussion!